Trial of Modafinil for Methamphetamine Dependence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00123370

Recruitment Status : Unknown

Verified July 2006 by The University of New South Wales.
Recruitment status was: Active, not recruiting

First Posted : July 22, 2005

Last Update Posted : May 1, 2007

Sponsor:

Collaborators:

Australian Government Department of Health and Ageing

Kirketon Road Centre, Sydney Hospital

St Vincent's Hospital, Sydney

Information provided by:

The University of New South Wales

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Primary Completion Date :	No date given
Estimated Study Completion Date :	September 2007

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Shearer J, Shanahan M, Darke S, Rodgers C, van Beek I, McKetin R, Mattick RP. A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence. Drug Alcohol Rev. 2010 May;29(3):235-42. doi: 10.1111/j.1465-3362.2009.00148.x.

Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J, Brady D, McKetin R, Mattick RP, Wodak A. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009 Feb;104(2):224-33. doi: 10.1111/j.1360-0443.2008.02437.x.

To Top